Stoke Therapeutics (NASDAQ:STOK) Shares Up 8.9% – Time to Buy?

Stoke Therapeutics, Inc. (NASDAQ:STOK) was up 8.9% during trading on Tuesday. The company traded as high as $27.11 and last traded at $27.0250. 279,721 shares traded hands during trading, a decline of 64% from the average daily volume of 783,479 shares. The stock had previously closed at $24.82.

Wall Street Analyst Weigh In

STOK has been the subject of several analyst reports. Wedbush upped their target price on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Chardan Capital reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Guggenheim reaffirmed a “buy” rating and set a $60.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Canaccord Genuity Group cut their price objective on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $44.25.

Stoke Therapeutics Price Performance

The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of -8.05 and a beta of 1.26. The firm’s fifty day moving average is $28.50 and its 200-day moving average is $30.49.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The company had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. On average, sell-side analysts expect that Stoke Therapeutics, Inc. will post -3.52 EPS for the current year.

Insider Transactions at Stoke Therapeutics

In other news, Director Edward Kaye sold 12,567 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $402,521.01. Following the sale, the director owned 124,557 shares in the company, valued at approximately $3,989,560.71. This represents a 9.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 1,051 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $26.16, for a total transaction of $27,494.16. Following the completion of the sale, the insider owned 19,059 shares in the company, valued at approximately $498,583.44. This trade represents a 5.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 34,594 shares of company stock valued at $1,069,305. Insiders own 9.60% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of STOK. Versant Capital Management Inc lifted its holdings in Stoke Therapeutics by 22.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,951 shares of the company’s stock worth $64,000 after buying an additional 359 shares during the last quarter. First Trust Advisors LP grew its position in shares of Stoke Therapeutics by 0.5% in the 1st quarter. First Trust Advisors LP now owns 163,459 shares of the company’s stock worth $5,322,000 after acquiring an additional 780 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Stoke Therapeutics in the 2nd quarter worth approximately $34,000. KBC Group NV bought a new stake in shares of Stoke Therapeutics in the 1st quarter valued at approximately $36,000. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Stoke Therapeutics by 195.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company’s stock valued at $60,000 after acquiring an additional 1,215 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc is a biotechnology company developing genetic medicines for severe diseases caused by inadequate protein expression. The company’s approach, known as TANGO (Targeted Augmentation of Nuclear Gene Output), uses antisense oligonucleotides to selectively modulate pre-messenger RNA splicing and increase production of functional proteins from disease-associated genes.

Stoke’s lead program is zorevunersen (STK-001), an investigational antisense oligonucleotide designed to increase functional NaV1.1 protein expression in people with Dravet syndrome, a severe genetic epilepsy caused primarily by mutations in the SCN1A gene.